Skip to main content

Drug Safety

3
Pipeline Programs
6
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
2100%
+ 3 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Patrys
PatrysAustralia - Melbourne
1 program
1
Anti-GRP78 monoclonal IgM antibody PAT-SM6Phase 11 trial
Active Trials
NCT01727778Completed12Est. Apr 2014
Entera Bio
Entera BioIsrael - Jerusalem
1 program
1
TeriparatidePhase 1Peptide1 trial
Active Trials
NCT02202603Completed42Est. Aug 2013
Biocorp
BiocorpFrance - Issoire
1 program
1
TeriparatidePhase 1Peptide
InflaRx
InflaRxJENA, Germany
1 program
CaCP29, a humanized monoclonal antibodyPHASE_11 trial
Active Trials
NCT01319903Completed26Est. Oct 2011
GE HealthCare
1 program
IodixanolPHASE_41 trial
Active Trials
NCT01475097Completed255Est. Feb 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GE HealthCareIodixanol
PatrysAnti-GRP78 monoclonal IgM antibody PAT-SM6
Entera BioTeriparatide
InflaRxCaCP29, a humanized monoclonal antibody

Clinical Trials (4)

Total enrollment: 335 patients across 4 trials

NCT01475097GE HealthCareIodixanol

Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography

Start: Oct 2011Est. completion: Feb 2013255 patients
Phase 4Completed
NCT01727778PatrysAnti-GRP78 monoclonal IgM antibody PAT-SM6

Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma

Start: Oct 2012Est. completion: Apr 201412 patients
Phase 1Completed
NCT02202603Entera BioTeriparatide

A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects

Start: Jul 2011Est. completion: Aug 201342 patients
Phase 1Completed
NCT01319903InflaRxCaCP29, a humanized monoclonal antibody

Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29

Start: Mar 2011Est. completion: Oct 201126 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.